Cargando…
Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis
Multiple sclerosis (MS) is caused by immune-mediated damage of myelin sheath. Current therapies aim to block such immune responses. However, this blocking is not sufficiently specific and hence compromises immunity, leading to severe side effects. In addition, blocking medications usually provide tr...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Federation of American Societies for Experimental Biology
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471518/ https://www.ncbi.nlm.nih.gov/pubmed/28363955 http://dx.doi.org/10.1096/fj.201601243R |
_version_ | 1783243962359742464 |
---|---|
author | Li, Chih-Huang Zhang, Jintao Baylink, David J. Wang, Xiaohua Goparaju, Naga Bharani Xu, Yi Wasnik, Samiksha Cheng, Yanmei Berumen, Edmundo Carreon Qin, Xuezhong Lau, Kin-Hing William Tang, Xiaolei |
author_facet | Li, Chih-Huang Zhang, Jintao Baylink, David J. Wang, Xiaohua Goparaju, Naga Bharani Xu, Yi Wasnik, Samiksha Cheng, Yanmei Berumen, Edmundo Carreon Qin, Xuezhong Lau, Kin-Hing William Tang, Xiaolei |
author_sort | Li, Chih-Huang |
collection | PubMed |
description | Multiple sclerosis (MS) is caused by immune-mediated damage of myelin sheath. Current therapies aim to block such immune responses. However, this blocking is not sufficiently specific and hence compromises immunity, leading to severe side effects. In addition, blocking medications usually provide transient effects and require frequent administration, which further increases the chance to compromise immunity. In this regard, myelin-specific therapy may provide the desired specificity and a long-lasting therapeutic effect by inducing myelin-specific regulatory T (T(reg)) cells. Tolerogenic dendritic cells (TolDCs) are one such therapy. However, ex vivo generated TolDCs may be converted into immunogenic DCs in a proinflammatory environment. In this study, we identified a potential novel myelin-specific therapy that works with immunogenic DCs, hence without the in vivo conversion concern. We showed that immunization with DCs, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase for de novo synthesis of a focally high 1,25-dihydroxyvitamin D concentration in the peripheral lymphoid tissues, induced T(reg) cells. In addition, such engineered DCs, when pulsed with a myelin antigen, led to myelin-specific suppression of ongoing experimental allergic encephalomyelitis (an MS animal model), and the disease suppression depended on forkhead-box-protein-P3(foxp3)(+) T(reg) cells. Our data support a novel concept that immunogenic DCs can be engineered for myelin-specific therapy for MS.—Li, C.-H., Zhang, J., Baylink, D. J., Wang, X., Goparaju, N. B., Xu, Y., Wasnik, S., Cheng, Y., Berumen, E. C., Qin, X., Lau, K.-H. W., Tang, X. Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis. |
format | Online Article Text |
id | pubmed-5471518 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Federation of American Societies for Experimental Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-54715182017-06-21 Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis Li, Chih-Huang Zhang, Jintao Baylink, David J. Wang, Xiaohua Goparaju, Naga Bharani Xu, Yi Wasnik, Samiksha Cheng, Yanmei Berumen, Edmundo Carreon Qin, Xuezhong Lau, Kin-Hing William Tang, Xiaolei FASEB J Research Multiple sclerosis (MS) is caused by immune-mediated damage of myelin sheath. Current therapies aim to block such immune responses. However, this blocking is not sufficiently specific and hence compromises immunity, leading to severe side effects. In addition, blocking medications usually provide transient effects and require frequent administration, which further increases the chance to compromise immunity. In this regard, myelin-specific therapy may provide the desired specificity and a long-lasting therapeutic effect by inducing myelin-specific regulatory T (T(reg)) cells. Tolerogenic dendritic cells (TolDCs) are one such therapy. However, ex vivo generated TolDCs may be converted into immunogenic DCs in a proinflammatory environment. In this study, we identified a potential novel myelin-specific therapy that works with immunogenic DCs, hence without the in vivo conversion concern. We showed that immunization with DCs, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase for de novo synthesis of a focally high 1,25-dihydroxyvitamin D concentration in the peripheral lymphoid tissues, induced T(reg) cells. In addition, such engineered DCs, when pulsed with a myelin antigen, led to myelin-specific suppression of ongoing experimental allergic encephalomyelitis (an MS animal model), and the disease suppression depended on forkhead-box-protein-P3(foxp3)(+) T(reg) cells. Our data support a novel concept that immunogenic DCs can be engineered for myelin-specific therapy for MS.—Li, C.-H., Zhang, J., Baylink, D. J., Wang, X., Goparaju, N. B., Xu, Y., Wasnik, S., Cheng, Y., Berumen, E. C., Qin, X., Lau, K.-H. W., Tang, X. Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis. Federation of American Societies for Experimental Biology 2017-07 2017-03-31 /pmc/articles/PMC5471518/ /pubmed/28363955 http://dx.doi.org/10.1096/fj.201601243R Text en © The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Li, Chih-Huang Zhang, Jintao Baylink, David J. Wang, Xiaohua Goparaju, Naga Bharani Xu, Yi Wasnik, Samiksha Cheng, Yanmei Berumen, Edmundo Carreon Qin, Xuezhong Lau, Kin-Hing William Tang, Xiaolei Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis |
title | Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis |
title_full | Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis |
title_fullStr | Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis |
title_full_unstemmed | Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis |
title_short | Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis |
title_sort | dendritic cells, engineered to overexpress 25-hydroxyvitamin d 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471518/ https://www.ncbi.nlm.nih.gov/pubmed/28363955 http://dx.doi.org/10.1096/fj.201601243R |
work_keys_str_mv | AT lichihhuang dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis AT zhangjintao dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis AT baylinkdavidj dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis AT wangxiaohua dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis AT goparajunagabharani dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis AT xuyi dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis AT wasniksamiksha dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis AT chengyanmei dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis AT berumenedmundocarreon dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis AT qinxuezhong dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis AT laukinhingwilliam dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis AT tangxiaolei dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis |